RCS - Yourgene Health PLC - The Healthcare+ Expo Taiwan

Yourgene HealthAnnouncement

05/12/2019 12:10

RNS Number : 8542V
Yourgene Health PLC
05 December 2019
 


 
Yourgene Health plc
("Yourgene" or the "Group" or the "Company")
 
The Healthcare+ Expo Taiwan
 
Manchester, UK - 5 December 2019: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces it will be exhibiting and presenting at The Healthcare+ Expo Taiwan, from the 5-8 December 2019 at stand R241, Hall 2 in the Taipei Nangang Exhibition Centre, Taiwan City, Taiwan.
 
The Expo brings together over 600 exhibitors, working in the advanced medicine and leading technology space and is a key Asia Pacific forum for interdisciplinary collaborations.
 
Two Key Opinion Leaders, Dr Min-Ji Charng and Dr Shu-Han You, will be making clinical educational presentations on behalf of Yourgene, along with a collaborating partner for bioinformatics for genomic research, Allen Chang. Details of the presentation are below:
 



Speaker:


Allen Chang, CEO ATgenomix




Topic:


Next Generation Bio-IT: A Unified High-quality Sequencing and High-performance Computing Solution for Genomics Research




Date:


6 December 2019




Time:


11:00 am CST (GMT +8)














Speaker:


Dr Min-Ji Charng, Director of Coronary Care Unit Taipei Veterans General Hospital




Topic:


Why cholesterol is so high in my family? Genetic testing for high cholesterol in Taiwan




Date:


6 December 2019




Time:   


2:00 pm CST (GMT +8)














Speaker:


Dr Shu-Han You, Lecturer & attending physician Chang Gung Memorial Hospital, Linkou




Topic:


Clinical Application of Whole Exome Sequencing in Prenatal and Postnatal Diagnosis




Date:    


6 December 2019




Time:


3:00 pm CST (GMT +8)



 
Lyn Rees, CEO of Yourgene Health plc, said: "We are particularly pleased to be showcasing all our products and services from the Taipei lab at the annual Taiwan Expo as well as having our clinical customers showcase their expertise with Yourgene's services."
 
 
 
 
 



Yourgene Health plc
Lyn Rees, Chief Executive Officer
Barry Hextall, Chief Financial Officer
Joanne Cross, Director of Marketing
 


Tel: +44 (0)161 669 8122
investors@yourgene-health.com
 














Stifel Nicolaus Europe Limited (Sole Corporate Broker)
Nicholas Moore / Matthew Blawat / Ben Maddison
 


Tel: +44 (0)20 7710 7600




Walbrook PR Ltd (Media and Investor Relations)
Paul McManus / Lianne Cawthorne
 
 
 
 
 


Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com
Mob: 07980 541 893 Mob: 07584 391 303
 








 
About Yourgene Health
Yourgene Health is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science. 
 
Yourgene develops and commercialises simple and accurate molecular diagnostic solutions, primarily for reproductive health. The Group's products include non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, male infertility tests and genetic disease tests. Yourgene's commercial footprint is already established in the UK, Europe, the Middle East, Africa and Asia.
 
Our product development, research service and commercial capabilities extend across the lifecycle of genetic test development including regulatory submissions. Through our technical expertise and partnerships, Yourgene Health is also extending its genetic testing offering into oncology.
 
Yourgene Health is headquartered in Manchester, UK with offices in Taipei and Singapore, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". For more information, visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRABDBDDXGGBGCU